The direct and indirect costs of acute myeloid leukemia were estimated for Sweden in 1989.
The calculated total cost was SEK 460 million.
Nearly half of the costs, or 1.7 million per patient diagnosed, were indirect costs due to premature mortality.
Direct costs of relapses and indirect costs of mortality represent costs due to the absence of completely curable therapy.
They also represent potential cost savings that could be obtained after introduction of new treatment options in the future.
Mots-clés Pascal : Leucémie myéloïde, Analyse coût, Homme, Suède, Europe, Economie santé, Traitement, Hémopathie maligne, Myéloprolifératif syndrome
Mots-clés Pascal anglais : Chronic myelocytic leukemia, Cost analysis, Human, Sweden, Europe, Health economy, Treatment, Malignant hemopathy, Myeloproliferative syndrome
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0094352
Code Inist : 002B19B. Création : 09/06/1995.